Tiziana Life Sciences Ltd Statistics
Share Statistics
Tiziana Life Sciences Ltd has 110.66M shares outstanding. The number of shares has increased by 2.48% in one year.
| Shares Outstanding | 110.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 71.76M |
| Failed to Deliver (FTD) Shares | 538 |
| FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 241.89K, so 0.23% of the outstanding shares have been sold short.
| Short Interest | 241.89K |
| Short % of Shares Out | 0.23% |
| Short % of Float | 0.36% |
| Short Ratio (days to cover) | 0.85 |
Valuation Ratios
The PE ratio is -3.06 and the forward PE ratio is -18.54.
| PE Ratio | -3.06 |
| Forward PE | -18.54 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.75 |
| P/FCF Ratio | -7.04 |
| PEG Ratio | n/a |
Enterprise Valuation
Tiziana Life Sciences Ltd has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 8.79, with a Debt / Equity ratio of 0.
| Current Ratio | 8.79 |
| Quick Ratio | 8.79 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.42 |
| Cash Flow / Debt | -58.13 |
| Interest Coverage | -112.81 |
Financial Efficiency
Return on equity (ROE) is -0.57% and return on capital (ROIC) is -319.08%.
| Return on Equity (ROE) | -0.57% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -319.08% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.97M |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 449.00K |
| Effective Tax Rate | 0.08 |
Stock Price Statistics
The stock price has increased by 65.14% in the last 52 weeks. The beta is 0.18, so Tiziana Life Sciences Ltd's price volatility has been higher than the market average.
| Beta | 0.18 |
| 52-Week Price Change | 65.14% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 0.85 |
| Relative Strength Index (RSI) | 46.97 |
| Average Volume (20 Days) | 272.63K |
Income Statement
In the last 12 months, Tiziana Life Sciences Ltd had revenue of $0 and earned -$17.69M in profits. Earnings per share was $0.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -17.98M |
| Net Income | -17.69M |
| EBITDA | -17.14M |
| EBIT | - |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has $1.18M in cash and $247.00K in debt, giving a net cash position of $936.00K.
| Cash & Cash Equivalents | 1.18M |
| Total Debt | 247.00K |
| Net Cash | 936.00K |
| Retained Earnings | -133.68M |
| Total Assets | 12.18M |
| Working Capital | 798.00K |
Cash Flow
In the last 12 months, operating cash flow was -$15.70M and capital expenditures $0, giving a free cash flow of -$15.70M.
| Operating Cash Flow | -15.70M |
| Capital Expenditures | 0 |
| Free Cash Flow | -15.70M |
| FCF Per Share | -0.08 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
TLSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0% |
| FCF Yield | -15.09% |
Analyst Forecast
Currently there are no analyst rating for TLSA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 21, 2021. It was a backward split with a ratio of 1:2.
| Last Split Date | Oct 21, 2021 |
| Split Type | backward |
| Split Ratio | 1:2 |
Scores
| Altman Z-Score | -10.32 |
| Piotroski F-Score | 2 |